08 July 2026
08 July 2026
The trial will enrol around 280 patients at up to 40 locations in the US and the Netherlands.
The study plans to enrol 400 participants living with early to mid-stage HD.
The collaboration leverages Biocytogen’s antibody capabilities and Whitehawk’s ADC expertise to identify BsADCs.
The platform is intended to help facilities with high turnover by increasing operating room throughput and procedural capacity.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
